Howard (Ted) Greene

Howard (Ted) Greene, Jr. is an accomplished entrepreneur and investor in the biotechnology industry

Mr. Greene was Chairman of Amylin Pharmaceuticals, Inc., a company he co-founded in 1987 that has launched two first-in-class diabetes drugs.

Before starting Amylin, Mr. Greene co-founded Biovest Partners, a venture capital firm that in two years provided seed capital and management leadership for six medical technology start-up companies, including Amylin, and that returned about ten-fold its limited partners' investment in less than five years.

Prior to Biovest, Mr. Greene was Chief Executive Officer of Hybritech Incorporated, essentially from inception until its acquisition by Eli Lilly and Company in 1986.

Before Hybritech, Mr. Greene was an executive with Baxter Healthcare Corporation for five years, and prior to that he was a consultant with McKinsey & Company for seven years.

He is presently a director of several early stage startups in the biotech and internet fields. Mr. Greene holds a Masters of Business Administration from Harvard University and a BA in physics from Amherst College.

Howard (Ted) Greene is the Board of Directors at Ocunexus Therapeutics. With a background in Biotechnology, Howard (Ted) Greene has a rich history of leadership and innovation.Howard (Ted) Greene studied MBA Business Administration at Harvard University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.